| Bart De Strooper | |
|---|---|
| Photo placeholder | |
| Affiliations | KU Leuven UK Dementia Research Institute |
| Country | Belgium/UK |
| H-index | 180 |
| ORCID | 0000-0002-9729-9478 |
| Research Focus | [Alzheimer's Disease](/diseases/alzheimers), Frontotemporal Dementia |
| Mechanisms | [Gamma-secretase](/entities/gamma-secretase), [APP](/entities/app-protein) Processing, [Amyloid](/mechanisms/amyloid-cascade) |
Bart De Strooper is a leading researcher in the field of neurodegenerative diseases, affiliated with KU Leuven and UK Dementia Research Institute. Their research focuses on Gamma-secretase, APP Processing, Amyloid, with particular emphasis on Alzheimer's Disease and Frontotemporal Dementia. With an h-index of 180, Strooper is among the most cited researchers in the neuroscience field[1].
Strooper's work spans multiple aspects of neurodegeneration, contributing to our understanding of the molecular mechanisms that underlie diseases such as Alzheimer's Disease and Frontotemporal Dementia. Their research group has made significant contributions to the fields of Gamma-secretase, APP Processing, Amyloid, publishing in high-impact journals including Nature Reviews Neuroscience.
Based at KU Leuven and UK Dementia Research Institute, Strooper collaborates with researchers across multiple institutions worldwide, working to advance therapeutic strategies for neurodegenerative conditions.
Strooper's portfolio emphasizes mechanism-aware biomarker interpretation and translational hypothesis testing in Alzheimer's Disease and Frontotemporal Dementia[2]. Their group typically links molecular process readouts to clinically meaningful outcomes, including cognitive trajectories, motor phenotypes, and disease staging endpoints when relevant.
The work frequently sits at the interface of discovery science and implementation, using study designs that can be transferred from observational cohorts to interventional studies. This makes the profile especially relevant for NeuroWiki pages that connect molecular mechanisms to treatment strategy, trial design, and patient stratification.
Within the Gamma-secretase, APP Processing, Amyloid domain, this research profile is most aligned with multimodal integration: combining imaging, biofluid, genomic, and clinical metadata to derive robust disease signatures. In practice, this means prioritizing reproducibility (cohort harmonization, independent replication, and transparent analysis assumptions) over one-off findings.
The program also supports comparative interpretation across related disorders, helping distinguish disease-general stress biology from disease-specific pathomechanisms. That distinction is important for mechanistic ranking and for selecting therapeutic targets with realistic translational potential.
For NeuroWiki readers, the translational value of this researcher profile lies in three areas: first, operationalizing mechanism-informed biomarkers for diagnosis and progression tracking; second, identifying patient subgroups most likely to respond to targeted interventions; and third, connecting preclinical hypotheses to trial-ready outcome frameworks.
This orientation improves actionability of mechanistic knowledge graphs because it links entities and pathways to measurable clinical decisions. Pages connected to this profile should therefore prioritize explicit mechanism-to-outcome chains, with clear assumptions and evidence quality labels.
Recent PubMed-indexed publications (2024-2026):
Collaborator network pending enrichment.
Primary institutional links: KU Leuven, UK Dementia Research Institute. These organizations provide critical infrastructure for longitudinal cohorts, mechanistic phenotyping, and translational trial partnerships in neurodegeneration research.
Phagocytes as plaque catalysts: Human macrophages generate seeding-competent Aβ40/42. Proc Natl Acad Sci U S A. 2026 Mar 10.
The Alzheimer's therapeutic Lecanemab attenuates Aβ pathology by inducing an amyloid-specific antibody response. Nat Neurosci. 2026 Jan.
Bioenergetics and lipid metabolism in Alzheimer's disease: From cell biology to translation. J Intern Med. 2026 Jan.
The APOE isoforms differentially shape the transcriptomic and epigenomic landscape of microglia. Nat Commun. 2025 May 27.
Lecanemab preferentially binds to smaller aggregates present at early Alzheimer's disease pathology. Alzheimers Dement. 2025 Apr.
Long and Holtzman, Alzheimer disease an update on pathobiology and treatment strategies 2019. 2019. ↩︎
Proteases in the pathogenesis of Alzheimer's disease. Nature Reviews Neuroscience. 2018. ↩︎